 IDEAYA Biosciences, Inc. Nasdaq:IDYA, an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics, announced the effectiveness of the Collaboration, Option and License Agreement between IDEAYA and GlaxoSmithKline Intellectual Property No. 4 Limited GSK following clearance under the Hart-Scott-Rodino Antitrust Improvements Act HSR. Pursuant to the Collaboration, Option and License Agreement, IDEAYA received an upfront cash payment of 100 million from GSK. The strategic partnership in Synthetic Lethality includes IDEAYAs MAT2A, Pol Theta, and Werner Helicase programs. 